

Impact of Implementing a Pharmacist-Led System-Wide Hepatitis C Screening and Test-To-Treat Program

Michelle Coady, PharmD^{1,2}, Amanuel Kehasse, PharmD, PhD², Richard McCormack, DPh^{1,2}, Sarah Curtin, CPhT²
¹Comanche County Memorial Hospital; ²Clearway Health



Introduction

The World Health Organization (WHO)1 and U.S. national strategic² plan aim to achieve a 90% reduction in hepatitis C infection and increase hepatitis C (HCV) diagnoses by 90% by year 2030. However, the 2023 National Progress Report³ indicated acute hepatitis C infections have been steadily on the rise; a 60% and 7% increase from 2017 and 2022, respectively. A recent study shows 1 in 3 adults in the United States are not aware of their potentially life-threatening infection. At the time of diagnosis, around 20% of patients will already have serious liver damage, cirrhosis and/or end-stage liver disease. Results of a recent study highlighted the average national hepatitis C cure rate is 37%. This highlights the need for a comprehensive screening program for early diagnosis and linkage to care.

Objective

The purpose of this study is to evaluate the impact of pharmacist lead system wide Hepatitis C screening and linkage to care workflow in Rural Community Health Center.


Rates* of reported cases¹ of acute hepatitis C virus infection, by state or jurisdiction — United States, 20214

Cases per 100,000 Population
Data unavailable
No reported case
0.4-0.8
15-2.6
Not reportable
0.0-0.3

2.7-9.8

Methodology

- Study Design: Retrospective observational descriptive study
- Data Source: HCV lab data pulled from VigiLanz, the lab software at Comanche County Memorial Hospital (CCMH)
- Study Population: Patients who had HCV tests conducted at the CCMH lab between April 1, 2023 and April 30, 2024.
- Exclusion: Patients who were not tested at the CCMH lab, but receiving treatment for HCV were excluded from the study.
- Statistical Analysis: Descriptive Statistics:
 Data presented as numbers and percentage.



Discussion

Significant attrition exists in the hepatitis C treatment cascade. To address this problem, we conceptualized a pharmacist-led system wide hepatitis C (HCV) screening and linkage to care program. The pharmacy department collaborated with the Family Medicine Residency Program at Lawton Community Health Center to create a linkage to care for patients with or without a primary care provider. In this pharmacist-led test-to-treat model, a pharmacist monitors the HCV screening lab results dashboard that is refreshed weekly. When an HCV-infected patient is identified, the pharmacist contacts the lab ordering provider to facilitate a discussion of the diagnosis with the patient, refer the patient to the HCV clinic and ensure linkage to care. Once treatment is started, the pharmacist follows up with patients at 4 weeks, 8 weeks, end-of-treatment (EOT), and ensures that EOT and 12-week SVR labs are completed.

During the 4 months of our study, our health system screened 1,416 patients. We identified 39 patients with detectable HCV RNA; out of which 67% were linked to HCV care and started treatment.

Compared with the preceding year (2023), the pharmacist-led test-to-treat model resulted in a 116% increase in the linkage to HCV care.

Overall, implementing a pharmacist-led, clinical dashboard supported, test-to-treat protocol helps to minimize attrition rate in the HCV treatment cascade and improves linkage to care, medication access and adherence.

References

- https://www.who.int/health-topics/hepatitis/eli mination-of-hepatitis-by-2030#tab=tab_1
- 2. https://www.cdc.gov/hepatitis/statistics/surveil lanceguidance/HepatitisC.htm
- 3. https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf
- 4. https://www.cdc.gov/hepatitis/policy/npr/2023 /index.htm
- 5. https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-c/figure-3.3.htm

Liaison

Acknowledgments

Dr. Mercades Bernard, DO
Dr. Gretchen Stroud, DO
Dr. Lindsay Stoops, DO
Dr. Nathan Blacker, DO
Dr. Daniel Joyce, DO
Seth Julian, DPh

Cheryl Hale, DPh, Director of Pharmacy Kendra Knox, CPhT, Pharmacy Liaison Shannon Haraer. CPhT. Pharmacy

Derek Dennis, PharmD, VP Client Services Christopher Wilson, PharmD, MBA, Regional Director